Traduction de «health – medical nutrition business unit » (Néerlandais → Français) :

Consumer Health – Medical Nutrition Business Unit On July 1, Novartis completed the divestment of the remainder of the Medical Nutrition Business Unit for approximately USD 2.5 billion to Nestlé S.A. resulting in a pre-tax divestment gain of USD 1.8 billion and an after-tax gain of USD 1.6 billion.
Consumer Health – unité d’affaires Nutrition médicale Le 1 er juillet, Novartis a finalisé la cession du reste de son unité d’affaires Nutrition médicale à Nestlé S.A. pour environ USD 2,5 milliards. Il en est résulté un gain de cession avant impôts d’USD 1,8 milliard et un gain après impôts d’USD 1,6 milliard.

Consumer Health – Gerber Business Unit On September 1, Novartis completed the divestment of the Gerber infant products Business Unit for approximately USD 5.5 billion to Nestlé S.A. resulting in a pre-tax divestment gain of approximately USD 4.0 billion and an after-tax gain of USD 3.6 billion.
Consumer Health – unité d’affaires Gerber Le 1 er septembre, Novartis a finalisé la cession de l’unité d’affaires Gerber alimentation pour bébés à Nestlé S.A. pour un montant d’environ USD 5,5 milliards. Il en est résulté un gain de cession avant impôts d’USD 4,0 milliards environ et un gain après impôts d’USD 3,6 milliards.

King’s three key businesses are not only complementary to Pfizer’s businesses, but are also strategically aligned with Pfizer’s Primary Care, Established Products and Animal Health business units, enabling a seamless combination that will maximize King’s assets with Pfizer’s global organization’s scale and resources.
King’s three key businesses are not only complementary to Pfizer’s businesses, but are also strategically aligned with Pfizer’s Primary Care, Established Products and Animal Health business units, enabling a seamless combination that will maximize King’s assets with Pfizer’s global organization’s scale and resources.

The Novartis Over-the-Counter (OTC) business unit generated positive growth with pain medications including Voltaren, a treatment for joint and muscle pain, which in the second quarter reached record market share as the second largest in the German OTC market.
L’unité d’affaires OTC (médicaments en vente libre) a affiché une bonne progression notamment avec ses analgésiques comprenant Voltaren, un traitement des articulations et des muscles. Celui-ci a atteint, au deuxième trimestre, une part record en Allemagne, ce qui le place au deuxième rang du marché OTC dans ce pays.

Novartis Consumer Health wordt in België vertegenwoordigd door 2 business units: Novartis Consumer Health OTC, producten voor het grote publiek alsook geneesmiddelen verkrijgbaar zonder voorschrift en CIBA VISION, producten en diensten bestemd om het zicht te corrigeren of de gezondheid van de ogen op peil te houden.
Novartis Consumer Health est représentée en Belgique à travers 2 unités d’affaires : Novartis Consumer Health OTC, produits grand public et d’automédication et CIBA VISION, produits et services destinés à corriger la vision ou entretenir la santé oculaire.

In België bestaat Novartis uit meerdere divisies: Novartis Pharma (bestaande uit 3 business units: General Medicines, Vaccins en Oncologie), Sandoz, Novartis Consumer Health en Alcon Eye Care.
En Belgique, Novartis compte plusieurs divisions: Novartis Pharma (comprenant 3 business units: General Medicines, Vaccins et Oncologie), Sandoz, Novartis Consumer Health OTC et Alcon Eye Care.

In België telt Novartis volgende divisies: Novartis Pharma (bestaande uit 2 business units: General Medicines en Oncology), Sandoz, Novartis Consumer Health OTC en CIBA VISION.
En Belgique, Novartis est composée de plusieurs divisions: Novartis Pharma (comprenant 2 business units: General Medicines et Oncologie), Sandoz, Novartis Consumer Health OTC et CIBA VISION.

At the center of any NEM lies a core team including senior managers in key functions (such as business unit heads, health and safety, security, quality or communications).
Le bon fonctionnement du NEM est assuré par la présence, au sein de chaque équipe, d’un petit groupe de dirigeants expérimentés occupant des fonctions clés (chefs d’unités ou collaborateurs actifs dans les domaines santé et sécurité, surveillance, qualité ou communication).

Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office DGO - SCM guidance committee (with APB and OPHACO) e-MED (electronic prescription of medicines) (with FPS Public Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Guidance committee of the network of medicalpharmaceutical committees ICVV – CICSA Influenza (in cooperation with external partners) Interdepartmental committee of experts on blood, organs, cells, tissues and embryos (with FPS Public Health, KCE, RIZIV - INAMI and WIV - ISP) Inter DG drugs (with FPS Public Health) Mdeon board of management Potassium iodide tablets campaign (with FPS Interior Affairs) Provincial medical commissions (with FPS Public Health) Strategic unit/RIZIV – INAMI Unavailability of medicines (with RIZIV - INAMI)
Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office DGO - SCM guidance committee (with APB and OPHACO) e-MED (electronic prescription of medicines) (with FPS Public Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Guidance committee of the network of medicalpharmaceutical committees ICVV – CICSA Influenza (in cooperation with external partners) Interdepartmental committee of experts on blood, organs, cells, tissues and embryos (with FPS Public Health, KCE, RIZIV - INAMI and WIV - ISP) Inter DG drugs (with FPS Public Health) Mdeon board of management Potassium iodide tablets campaign (with FPS Interior Affairs) Provincial medical commissions (with FPS Public Health) Strategic unit/RIZIV – INAMI Unavailability of medicines (with RIZIV - INAMI)

Prof. Dr. Beutels Philippe (University Antwerp), Ms. Dewilde Sarah MSc (Health Care Analytics Group, United BioSource Corporation), Dr. Lamers Leida (iMTA and Erasmus University Medical Center, NL), Prof. Dr. Robays Hugo (UGent), Mrs. Rumeau-Pichon Catherine (Health economics and public health (HAS), FR), Prof. Dr. Simoens Steven (KULeuven), Dr. Van Eeckhout Herman (Pharma.be).
Beutels Philippe (University Antwerp), Dewilde Sarah MSc (Health Care Analytics Group, United BioSource Corporation), Lamers Leida (iMTA and Erasmus University Medical Center, NL), Robays Hugo (UGent), Rumeau- Pichon Catherine (Health economics and public health (HAS), FR), Simoens Steven (KULeuven), Van Eeckhout Herman (Pharma.be).